Study Supports Longer ADT Use With Radiation for High-Risk Prostate Cancer
Study findings suggest a longer ADT duration than NCCN guidelines for patients with high-risk prostate cancer treated with EBRT alone.
Medications
Fosfomycin May Have Place in Treating Drug-Resistant Bacteremic UTIs
In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with these infections, according to investigators.
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis
Hyperphosphatemia Slightly Reduces Calcimimetics’ Effects
Study findings suggest serum phosphate is a negative modulator of calcium receptor activation.
High-Dose IV Iron Reduces Myocardial Infarction in Hemodialysis
Until now, no other treatment has been shown to reduce heart attack risk in patients on dialysis.
Efficacy of Bamlanivimab for COVID-19 May Vary With Antibody Status
Further study needed to determine whether bamlanivimab could benefit patients who are negative for endogenous neutralizing antibodies
Gene Polymorphism Might Influence Cinacalcet Response
A recent findings, if validated, may partly explain inter-individual differences in the response to cinacalcet treatment for secondary hyperparathyroidism.
Three Days of Remdesivir Cuts Risk for Severe COVID-19 in Outpatients
Three-day course of treatment results in reduced risk for hospitalization or death compared with placebo
Use of Certain Prescription Meds Linked to COVID-19 Mortality
Discontinuation of ACE-I, ARB, metformin associated with elevated risk for death among hospitalized COVID-19 patients
Inequities Seen in GLP-1 RA Use for Type 2 Diabetes in the US
Asian, Black, Hispanic, and low-income patients less likely to receive treatment with a glucagon-like peptide-1 receptor agonist for T2DM
- Loading...
Loading...
Next post in Diabetes
Loading... 
Loading...